Clinical implications of molecular genetic aberrations in acute myeloid leukemia

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 4, 2009, Pages 491-505

  Scholl, Sebastian ^a   Fricke, Hans Joerg ^a   Sayer, Herbert G ^a   Höffken, Klaus ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

AML; MRD; Mutations; Prognosis

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CORE BINDING FACTOR BETA; MICRORNA; MIXED LINEAGE LEUKEMIA PROTEIN; MOLECULAR MARKER; NUCLEOPHOSMIN; PROTEIN BAALC; RAS PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR EVI1; TRANSCRIPTION FACTOR MN1; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; BLAST CELL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; HUMAN; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; REVIEW;

CCAAT-ENHANCER-BINDING PROTEINS; CHROMOSOME ABERRATIONS; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; GENE FREQUENCY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR BIOLOGY; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN-TYROSINE KINASES; SURVIVAL ANALYSIS; WT1 PROTEINS;

EID: 61449204716     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0524-x     Document Type: Review

References (96)

1. A Andersson B Johansson C Lassen F Mitelman R Billström T Fioretos 2004 Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients Eur J Haematol 72 307 313 10.1111/j.1600-0609.2004.00225.x
2. U Bacher T Haferlach C Schoch W Kern S Schnittger 2006 Implications of NRAS mutations in AML: a study of 2,502 patients Blood 107 3847 3853 10.1182/blood-2005-08-3522
3. U Bacher C Haferlach W Kern T Haferlach S Schnittger 2008 Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients Blood 111 2527 2537 10.1182/blood-2007-05-091215
4. CD Baldus SM Tanner AS Ruppert SP Whitman KJ Archer G Marcucci MA Caligiuri AJ Carroll JW Vardiman BL Powell SL Allen JO Moore RA Larson JE Kolitz A de la Chapelle CD Bloomfield 2003 BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study Blood 102 1613 1618 10.1182/blood-2003-02-0359
5. CD Baldus C Thiede S Soucek CD Bloomfield E Thiel G Ehninger 2006 BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications J Clin Oncol 24 790 797 10.1200/JCO.2005.01.6253
6. MY Balkhi AK Trivedi M Geletu M Christopeit SK Bohlander HM Behre G Behre 2006 Proteomics of acute myeloid leukaemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications Oncogene 25 7041 7058 10.1038/sj.onc.1209689
7. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Meijer J, van Oosterhoud S, van Putten WL, Valk PJ, Berna Beverloo H, Tenen DG, Löwenberg B, Delwel R (2003a) Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 4:31-40. doi: 10.1038/sj.thj.6200216
8. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB, Verhoef G, Verdonck LF, Ossenkoppele GJ, Sonneveld P, de Greef GE, Löwenberg B, Delwel R (2003b) High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101:837-845. doi: 10.1182/blood-2002-05-1459
9. M Bienz M Ludwig EO Leibundgut BU Mueller D Ratschiller M Solenthaler MF Fey T Pabst 2005 Risk assessment in patients with acute myeloid leukemia and a normal karyotype Clin Cancer Res 11 1416 1424 10.1158/1078-0432.CCR-04-1552
10. N Boissel H Leroy B Brethon N Philippe S de Botton A Auvrignon E Raffoux T Leblanc X Thomas O Hermine B Quesnel A Baruchel G Leverger H Dombret C Preudhomme 2006 Acute Leukemia French Association (ALFA); Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups: incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) Leukemia 20 965 970 10.1038/sj.leu.2404188
11. M Bornhäuser T Illmer M Schaich S Soucek G Ehninger C Thiede 2007 AML SHG 96 study group: improved outcome after stemcell transplantation in FLT3/ITD positive AML Blood 109 2264 2265 10.1182/blood-2006-09-047225
12. DT Bowen ME Frew R Hills RE Gale K Wheatley MJ Groves SE Langabeer PD Kottaridis AV Moorman AK Burnett DC Linch 2005 RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years Blood 106 2113 2119 10.1182/blood-2005-03-0867
13. L Bullinger K Döhner E Bair S Fröhling RF Schlenk R Tibshirani H Döhner JR Pollack 2004 Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia N Engl J Med 350 1605 1616 10.1056/NEJMoa031046
14. L Bullinger FG Rücker S Kurz J Du C Scholl S Sander A Corbacioglu C Lottaz J Krauter S Fröhling A Ganser RF Schlenk K Döhner JR Pollack H Döhner 2007 Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia Blood 110 1291 1300 10.1182/blood-2006-10-049783
15. L Bullinger K Döhner R Kranz C Stirner S Fröhling C Scholl YH Kim RF Schlenk R Tibshirani H Döhner JR Pollack 2008 An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML Blood 111 4490 4495 10.1182/blood-2007-09-115055
16. S Buonamici E Ottaviani N Testoni V Montefusco G Visani F Bonifazi M Amabile C Terragna D Ruggeri PP Piccaluga A Isidori M Malagola M Baccarani S Tura G Martinelli 2002 Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state Blood 99 443 449 10.1182/blood.V99.2.443
17. AK Burnett J Kell 2007 Tipifarnib in acute myeloid leukemia Drugs Today (Barc) 43 795 800
18. R Cairoli A Beghini G Grillo G Nadali F Elice CB Ripamonti P Colapietro M Nichelatti L Pezzetti M Lunghi A Cuneo A Viola F Ferrara M Lazzarino F Rodeghiero G Pizzolo L Larizza E Morra 2006 Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study Blood 107 3463 3468 10.1182/blood-2005-09-3640
19. MA Caligiuri SA Schichman MP Strout K Mrózek MR Baer SR Frankel M Barcos GP Herzig CM Croce CD Bloomfield 1994 Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations Cancer Res 54 370 373
20. C Callens S Chevret JM Cayuela B Cassinat E Raffoux S de Botton X Thomas A Guerci N Fegueux A Pigneux AM Stoppa T Lamy F Rigal-Huguet A Vekhoff S Meyer-Monard A Ferrand M Sanz C Chomienne P Fenaux H Dombret 2005 European APL Group: prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group Leukemia 19 1153 1160 10.1038/sj.leu.2403790
21. B Cassinat F Zassadowski N Balitrand C Barbey JD Rain P Fenaux L Degos M Vidaud C Chomienne 2000 Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR Leukemia 14 324 328 10.1038/sj.leu.2401652
22. G Cazzaniga MG Dell'Oro C Mecucci E Giarin R Masetti V Rossi F Locatelli MF Martelli G Basso A Pession A Biondi B Falini 2005 Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype Blood 106 1419 1422 10.1182/blood-2005-03-0899
23. WC Chou JL Tang SJ Wu W Tsay M Yao SY Huang KC Huang CY Chen CF Huang HF Tien 2007 Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations Leukemia 21 998 1004
24. C Choudhary J Schwäble C Brandts L Tickenbrock B Sargin T Kindler T Fischer WE Berdel C Müller-Tidow H Serve 2005 AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations Blood 106 265 273 10.1182/blood-2004-07-2942
25. JW Cui J Wang K He BF Jin HX Wang W Li 2004 Proteomic analysis of human acute leukemia cells: insight into their classification Clin Cancer Res 10 6887 6896 10.1158/1078-0432.CCR-04-0307
26. K Döhner K Tobis R Ulrich S Fröhling A Benner RF Schlenk H Döhner 2002 Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16-60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm J Clin Oncol 20 3254 3261 10.1200/JCO.2002.09.088
27. K Döhner RF Schlenk M Habdank C Scholl FG Rücker A Corbacioglu L Bullinger S Fröhling H Döhner 2005 Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations Blood 106 3740 3746 10.1182/blood-2005-05-2164
28. B Falini C Mecucci E Tiacci M Alcalay R Rosati L Pasqualucci R La Starza D Diverio E Colombo A Santucci B Bigerna R Pacini A Pucciarini A Liso M Vignetti P Fazi N Meani V Pettirossi G Saglio F Mandelli F Lo-Coco PG Pelicci MF Martelli 2005 GIMEMA Acute Leukemia Working Party: cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype N Engl J Med 352 254 266 10.1056/NEJMoa041974
29. S Fröhling RF Schlenk J Breitruck A Benner S Kreitmeier K Tobis H Döhner K Döhner 2002 AML Study Group Ulm: acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm Blood 100 4372 4380 10.1182/blood-2002-05-1440
30. S Fröhling RF Schlenk I Stolze J Bihlmayr A Benner S Kreitmeier K Tobis H Döhner K Döhner 2004 CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations J Clin Oncol 22 624 633 10.1200/JCO.2004.06. 060
31. RE Gale R Hills AR Pizzey PD Kottaridis D Swirsky AF Gilkes E Nugent KI Mills K Wheatley E Solomon AK Burnett DC Linch D Grimwade 2005 NCRI Adult Leukaemia Working Party: Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia Blood 106 3768 3776 10.1182/blood-2005-04-1746
32. RE Gale R Hills PD Kottaridis S Srirangan K Wheatley AK Burnett DC Linch 2005 No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1,135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials Blood 106 3658 3665 10.1182/blood-2005-03-1323
33. R Garzon M Garofalo MP Martelli R Briesewitz L Wang C Fernandez-Cymering S Volinia CG Liu S Schnittger T Haferlach A Liso D Diverio M Mancini G Meloni R Foa MF Martelli C Mecucci CM Croce B Falini 2008 Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin Proc Natl Acad Sci USA 105 3945 3950 10.1073/pnas.0800135105
34. KV Gleixner M Mayerhofer KJ Aichberger S Derdak K Sonneck A Böhm A Gruze P Samorapoompichit PW Manley D Fabbro WF Pickl C Sillaber P Valent 2006 PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects Blood 107 752 759 10.1182/blood-2005-07-3022
35. AF Gombart WK Hofmann S Kawano S Takeuchi U Krug SH Kwok RJ Larsen H Asou CW Miller D Hoelzer HP Koeffler 2002 Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias Blood 99 1332 1340 10.1182/blood.V99.4. 1332
36. P Gorello G Cazzaniga F Alberti MG Dell'Oro E Gottardi G Specchia G Roti R Rosati MF Martelli D Diverio F Lo Coco A Biondi G Saglio C Mecucci B Falini 2006 Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations Leukemia 20 1103 1108 10.1038/sj.leu.2404149
37. J Gotlib 2005 Farnesyltransferase inhibitor therapy in acute myelogenous leukemia Curr Hematol Rep 4 77 84
38. C Graf F Heidel S Tenzer MP Radsak FK Solem CM Britten C Huber T Fischer T Wölfel 2007 A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells Blood 109 2985 2988
39. GC Grosveld 2007 MN1, a novel player in human AML Blood Cells Mol Dis 39 336 339 10.1016/j.bcmd.2007.06.009
40. R Grundler C Miething C Thiede C Peschel J Duyster 2005 FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model Blood 105 4792 4799 10.1182/blood-2004-11-4430
41. K Haas M Kundi WR Sperr H Esterbauer WD Ludwig R Ratei E Koller H Gruener C Sauerland C Fonatsch P Valent R Wieser 2008 Expression and prognostic significance of different mRNA 5-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration Genes Chromosomes Cancer 47 288 298 10.1002/gcc.20532
42. M Heuser G Beutel J Krauter K Döhner N von Neuhoff B Schlegelberger A Ganser 2006 High meningeoma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics Blood 108 3898 3905 10.1182/blood-2006-04-014845
43. Y Hutchings T Osada CY Woo TM Clay HK Lyerly MA Morse 2007 Imunotherapeutic targeting of Wilms' tumor protein Curr Opin Mol Ther 9 62 69
44. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, Saunthararajah Y, Maciejewski JP (2008) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2008(Oct):2. Epub ahead of print
45. M Jongen-Lavrencic SM Sun MK Dijkstra PJ Valk B Löwenberg 2008 MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia Blood 111 5078 5085 10.1182/blood-2008-01-133355
46. L King-Underwood K Pritchard-Jones 1998 Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance Blood 91 2961 2968
47. Kornblau SM, Tibes R, Qiu Y, Chen W, Kantarjian HM, Andreeff M, Coombes KR, Mills GB (2008) Functional proteomic profiling of AML predicts response and survival. Blood 2008(Oct):7. Epub ahead of print
48. PD Kottaridis RE Gale ME Frew G Harrison SE Langabeer AA Belton H Walker K Wheatley DT Bowen AK Burnett AH Goldstone DC Linch 2001 The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 98 1752 1759 10.1182/blood.V98.6.1752
49. PD Kottaridis RE Gale SE Langabeer ME Frew DT Bowen DC Linch 2002 Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors Blood 100 2393 2398 10.1182/blood-2002-02-0420
50. J Krauter W Hoellge MP Wattjes S Nagel O Heidenreich D Bunjes A Ganser G Heil 2001 Detection and quantification of CBFB/MYH11 fusion transcripts in patiens with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR Genes Chromosomes Cancer 30 342 348 10.1002/gcc.1100
51. J Krauter K Gorlich O Ottmann M Lubbert H Dohner W Heit L Kanz A Ganser G Heil 2003 Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias J Clin Oncol 21 4413 4422 10.1200/JCO.2003.03.166
52. H Kroeger J Jelinek MR Estécio R He K Kondo W Chung L Zhang L Shen HM Kantarjian CE Bueso-Ramos JP Issa 2008 Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse Blood 112 1366 1373 10.1182/blood-2007-11-126227
53. F Kuchenbauer C Schoch W Kern W Hiddemann T Haferlach S Schnittger 2005 Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia Br J Haematol 130 196 202 10.1111/j.1365-2141.2005.05595.x
54. C Langer MD Radmacher AS Ruppert SP Whitman P Paschka K Mrózek CD Baldus T Vukosavljevic CG Liu ME Ross BL Powell A de la Chapelle JE Kolitz RA Larson G Marcucci CD Bloomfield 2008 Cancer and Leukemia Group B (CALGB): high BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) Study Blood 111 5371 5379 10.1182/blood-2007-11-124958
55. Z Li J Lu M Sun S Mi H Zhang RT Luo P Chen Y Wang M Yan Z Qian MB Neilly J Jin Y Zhang SK Bohlander DE Zhang RA Larson MM Le Beau MJ Thirman TR Golub JD Rowley J Chen 2008 Distinct microRNA expression profiles in acute myeloid leukemia with common translocations Proc Natl Acad Sci USA 105 15535 15540 10.1073/pnas.0808266105
56. S Lugthart E van Drunen Y van Norden A van Hoven CA Erpelinck PJ Valk HB Beverloo B Löwenberg R Delwel 2008 High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated Blood 111 4329 4337 10.1182/blood-2007-10- 119230
57. G Marcucci KJ Livak W Bi MP Strout CD Bloomfield MA Caligiuri 1998 Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay Leukemia 12 1482 1489 10.1038/sj.leu.2401128
58. G Marcucci CD Baldus AS Ruppert MD Radmacher K Mrózek SP Whitman JE Kolitz CG Edwards JW Vardiman BL Powell MR Baer JO Moore D Perrotti MA Caligiuri AJ Carroll RA Larson A de la Chapelle CD Bloomfield 2005 Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B Study J Clin Oncol 23 9234 9242 10.1200/JCO.2005.03.6137
59. G Marcucci K Maharry SP Whitman T Vukosavljevic P Paschka C Langer K Mrózek CD Baldus AJ Carroll BL Powell JE Kolitz RA Larson CD Bloomfield 2007 High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study J Clin Oncol 25 3337 3343 10.1200/JCO.2007.10.8720
60. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD (2008a) Prognostic significance of, and gene and microrna expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 2008(Sep):22. Epub ahead of print
61. G Marcucci MD Radmacher K Maharry K Mrózek AS Ruppert P Paschka T Vukosavljevic SP Whitman CD Baldus C Langer CG Liu AJ Carroll BL Powell R Garzon CM Croce JE Kolitz MA Caligiuri RA Larson CD Bloomfield 2008 MicroRNA expression in cytogenetically normal acute myeloid leukemia N Engl J Med 358 1919 1928 10.1056/NEJMoa074256
62. AJ Mead DC Linch RK Hills K Wheatley AK Burnett RE Gale 2007 FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia Blood 110 1262 1270 10.1182/blood-2006-04- 015826
63. C Meyer B Schneider S Jakob S Strehl A Attarbaschi S Schnittger C Schoch MW Jansen JJ van Dongen ML den Boer R Pieters MG Ennas 2006 The MLL recombinome of acute leukemias Leukemia 20 777 784 10.1038/sj.leu.2404150
64. I Moreno G Martín P Bolufer E Barragán E Rueda J Román P Fernández P León A Mena J Cervera A Torres MA Sanz 2003 Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia Haematologica 88 19 24
65. CG Mullighan A Kennedy X Zhou I Radtke LA Phillips SA Shurtleff JR Downing 2007 Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias Leukemia 21 2000 2009 10.1038/sj.leu.2404808
66. M Nakao S Yokota T Iwai H Kaneko S Horiike K Kashima Y Sonoda T Fujimoto S Misawa 1996 Internal tandem duplication of the flt3 gene found in acute myeloid leukemia Leukemia 10 1911 1918
67. NI Noguera M Breccia M Divona D Diverio V Costa S De Santis G Avvisati MB Pinazzi MC Petti F Mandelli F Lo Coco 2002 Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol Leukemia 11 2185 2189 10.1038/sj.leu.2402723
68. P Paschka G Marcucci AS Ruppert K Mrózek H Chen RA Kittles T Vukosavljevic D Perrotti JW Vardiman AJ Carroll JE Kolitz RA Larson CD Bloomfield 2006 Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study J Clin Oncol 24 3904 3911 10.1200/JCO.2006.06.9500
69. P Paschka G Marcucci AS Ruppert SP Whitman K Mrózek K Maharry C Langer CD Baldus W Zhao BL Powell MR Baer AJ Carroll MA Caligiuri JE Kolitz RA Larson CD Bloomfield 2008 Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study J Clin Oncol 26 4595 4602 10.1200/JCO.2007.15. 2058
70. C Preudhomme C Sagot N Boissel JM Cayuela I Tigaud S de Botton X Thomas E Raffoux C Lamandin S Castaigne P Fenaux H Dombret 2002 ALFA Group: favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) Blood 100 2717 2723 10.1182/blood-2002-03-0990
71. RF Schlenk K Döhner J Krauter S Fröhling A Corbacioglu L Bullinger M Habdank D Späth M Morgan A Benner B Schlegelberger G Heil A Ganser H Döhner 2008 German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 1909 1918 10.1056/NEJMoa074306
72. S Schnittger B Wörmann W Hiddemann F Griesinger 1998 Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors Blood 92 1728 1734
73. S Schnittger C Schoch M Dugas W Kern P Staib C Wuchter H Löffler CM Sauerland H Serve T Büchner T Haferlach W Hiddemann 2002 Analysis of FLT3 length mutations in 1,003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease Blood 100 59 66 10.1182/blood.V100.1.59
74. S Schnittger C Schoch W Kern W Hiddemann T Haferlach 2004 FLT3 length mutations as marker for follow-up studies in acute myeloid leukemia Acta Haematol 112 68 78 10.1159/000077561
75. S Schnittger C Schoch W Kern C Mecucci C Tschulik MF Martelli T Haferlach W Hiddemann B Falini 2005 Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype Blood 106 3733 3739 10.1182/blood-2005-06-2248
76. S Schnittger TM Kohl T Haferlach W Kern W Hiddemann K Spiekermann C Schoch 2006 KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival Blood 107 1791 1799 10.1182/blood-2005-04-1466
77. C Schoch A Kohlmann S Schnittger B Brors M Dugas S Mergenthaler W Kern W Hiddemann R Eils T Haferlach 2002 Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles Proc Natl Acad Sci USA 99 10008 10013 10.1073/pnas.142103599
78. S Scholl IF Loncarevic C Krause C Kunert JH Clement K Höffken 2005 Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia Leuk Res 29 849 853 10.1016/j.leukres.2004.12.001
79. S Scholl LO Mügge O Landt IF Loncarevic C Kunert JH Clement K Höffken 2007 Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia Leuk Res 31 1213 1219 10.1016/j.leukres.2006.12.011
80. NP Shah FY Lee R Luo Y Jiang M Donker C Akin 2006 Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis Blood 108 286 291 10.1182/blood-2005-10-3969
81. LY Shih CF Huang JH Wu TL Lin P Dunn PN Wang MC Kuo CL Lai HC Hsu 2002 Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse Blood 100 2387 2392 10.1182/blood-2002-01-0195
82. LY Shih CF Huang JH Wu PN Wang TL Lin P Dunn MC Chou MC Kuo CC Tang 2004 Heterogeneous patterns of Flt3 Asp835 mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples Clin Cancer Res 10 1326 1332 10.1158/1078-0432.CCR-0835-03
83. C Steudel M Wermke M Schaich U Schäkel T Illmer G Ehninger C Thiede 2003 Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia Genes Chromosomes Cancer 37 237 251 10.1002/gcc.10219
84. DL Stirewalt KJ Kopecky S Meshinchi FR Appelbaum ML Slovak CL Willman JP Radich 2001 FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia Blood 97 3589 3595 10.1182/blood.V97.11.3589
85. K Summers J Stevens I Kakkas M Smith LL Smith F Macdougall J Cavenagh D Bonnet BD Young TA Lister J Fitzgibbon 2001 Wilms' tumor 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML Leukemia 21 550 551 10.1038/sj.leu.2404514
86. T Suzuki H Kiyoi K Ozeki A Tomita S Yamaji R Suzuki 2005 Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia Blood 106 2854 2861 10.1182/blood-2005-04-1733
87. SM Tanner JL Austin G Leone LJ Rush C Plass K Heinonen K Mrózek H Sill S Knuutila JE Kolitz KJ Archer MA Caligiuri CD Bloomfield A de La Chapelle 2001 BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia Proc Natl Acad Sci USA 98 13901 13906 10.1073/pnas.241525498
88. C Thiede C Steudel B Mohr M Schaich U Schäkel U Platzbecker M Wermke M Bornhäuser M Ritter A Neubauer G Ehninger T Illmer 2002 Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 99 4326 4335 10.1182/blood.V99.12.4326
89. C Thiede S Koch E Creutzig C Steudel T Illmer M Schaich G Ehninger 2006 Prevalence and prognostic impact of NPM1 mutations in 1,485 adult patients with acute myeloid leukemia (AML) Blood 107 4011 4020 10.1182/blood-2005-08-3167
90. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Löwenberg B, Delwel R (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350:1617-1628. doi: 10.1056/NEJMoa040465
91. Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J, Allen C, Green C, Quentmeier H, Drexler H, Burnett A, Linch D, Bonnet D, Lister TA, Fitzgibbon J (2008) Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008(Jul):7. Epub ahead of print
92. Weisser M, Kern W, Schoch, Hiddemann W, Haferlach T, Schnittger S (2005) Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica 90:881-889
93. SP Whitman S Liu T Vukosavljevic LJ Rush L Yu C Liu MI Klisovic K Maharry M Guimond MP Strout B Becknell A Dorrance RB Klisovic C Plass CD Bloomfield G Marcucci MA Caligiuri 2005 The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy Blood 106 345 352 10.1182/blood-2005-01- 0204
94. SP Whitman AS Ruppert MD Radmacher K Mrózek P Paschka C Langer CD Baldus J Wen F Racke BL Powell JE Kolitz RA Larson MA Caligiuri G Marcucci CD Bloomfield 2008 FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications Blood 111 1552 1559 10.1182/blood-2007-08-107946
95. Y Yamamoto H Kiyoi Y Nakano R Suzuki Y Kodera S Miyawaki N Asou K Kuriyama F Yagasaki C Shimazaki H Akiyama K Saito M Nishimura T Motoji K Shinagawa A Takeshita H Saito R Ueda R Ohno T Naoe 2001 Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies Blood 97 2434 2439 10.1182/blood.V97.8.2434
96. M Yanada K Matsuo T Suzuki H Kiyoi T Naoe 2005 Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis Leukemia 19 1345 1349 10.1038/sj.leu.2403838